# DAREON-9 (NCT05990738)

> DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05990738
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Boehringer Ingelheim
- Conditions: Small Cell Lung Carcinoma (SCLC)
- Interventions: BI 764532; Topotecan; Single agent chemotherapy
- Enrollment: 69
- Primary outcome: Part A: Occurrence of dose limiting toxicities (DLTs) in the maximum tolerated dose (MTD) evaluation period
- Primary outcome: Part B: Occurrence of DLTs during the on-treatment period
- Primary outcome: Part B: Occurrence of AEs during the on-treatment period

## Indexed commentary on DAREON-9 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 2
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=dareon-9-nct05990738